Top

Cancer Causes & Control

Published in:

01-06-2008 | Review Article

Melanoma in relation to reproductive and hormonal factors in women: current review on controversial issues

Authors: Marko Lens, Veronique Bataille

Published in: Cancer Causes & Control | Issue 5/2008

Abstract

Purpose

About one third of all melanoma in women occur during their childbearing age. An association between melanoma and hormonal and reproductive factors remains controversial.

Methods

This article reviews current evidence on the link between melanoma and reproductive factors. A comprehensive search of Medline (from 1966 to July 2007) and Embase (1974 to July 2007) was performed. Articles were reviewed and additional references were obtained from the bibliographies.

Results

Several controversial issues have been discussed. A pooled analysis of 10 case–control studies including a total of 5,590 women found a lack of association between melanoma risk and pregnancy. Data suggested that women with higher parity (five or more live births) had moderately lower melanoma risk compared with nulliparous women. Current evidence demonstrated that pregnancy did not appear to affect survival in women with melanoma. Based on the current evidence there is no reason to recommend deferral of subsequent pregnancy in women in whom a primary melanoma is diagnosed during pregnancy. The data revealed no relation between melanoma risk and use of oral contraceptives and hormone replacement therapy (HRT).

Conclusion

Exogenous or endogenous female hormones do not contribute significantly to increased risk of melanoma. Melanoma prognosis does not appear to be affected by pregnancy. Termination of pregnancy in women diagnosed with a primary melanoma during pregnancy is not recommended. There is no evidence to support deferral of pregnancy in women with melanoma history except that at the end of 2 years patients have a better estimate of their risk of recurrence.

Marks R (2000) Epidemiology of melanoma. Clin Exp Dermatol 25:459–463PubMedCrossRef

Lens MB, Dawes M (2004) Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 150(2):179–185PubMedCrossRef

Whiteman DC, Stickley M, Watt P, Hughes MC, Davis MB, Green AC (2006) Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 24(19):3172–3177PubMedCrossRef

Colbourn DS, Nathanson L, Belilos E (1989) Pregnancy and melanoma. Semin Oncol 16:377–387PubMed

Potter JF, Schoeneman M (1970) Metastasis of maternal cancer to the placenta and fetus. Cancer 25:380–387PubMedCrossRef

Matthiasen L, Berg G (1989) Malignant melanoma, the most common cancer type, first appearing during pregnancy. Läkartidningen 86:2845–2848

Garbe C (1993) Pregnancy, hormone preparations and malignant melanoma. Hautarzt 44:347–352PubMed

Smith RS, Randall P (1969) Melanoma during pregnancy. Obstet Gynecol 34:825–829PubMed

Dillman RO, Vandermolen LA, Barth NM, Bransford KJ (1996) Malignant melanoma and pregnancy. West J Med 164:156–161PubMed

10.

Lens MB, Rosdahl I, Ahlbom A, Farahmand BY, Synnerstad I, Boeryd B et al (2004) Effect of pregnancy on survival in women with cutaneous malignant melanoma. J Clin Oncol 22(21):4369–4375PubMedCrossRef

11.

Ariel IM (1980) Theories regarding the cause of malignant melanoma. Surg Gynecol Obstet 150:907–917PubMed

12.

Karagas MR, Zens MS, Stukel TA, Swerdlow AJ, Rosso S, Osterlind A et al (2006) Pregnancy history and incidence of melanoma in women: a pooled analysis. Cancer Causes Control 17(1):11–19PubMedCrossRef

13.

Kaae J, Andersen A, Boyd HA, Wohlfahrt J, Melbye M (2007) Reproductive history and cutaneous malignant melanoma: a comparison between women and men. Am J Epidemiol 165(11):1265–1270PubMedCrossRef

14.

Pack GT, Scharnagel IM (1951) Prognosis of malignant melanoma in pregnant women. Cancer 4:324–334PubMedCrossRef

15.

Sutherland CM, Loutfi A, Mather FJ, Carter RD, Krementz ET (1983) Effect of pregnancy upon malignant melanoma. Surg Gynecol Obstet 157:443–446PubMed

16.

Trapeznikov NN, Khasanov SR, Iavorskii VV (1987) Melanoma of the skin and pregnancy. Voproxy Onkologii 33:40–46

17.

Byrd BF, McGanty WJ (1954) Effect of pregnancy on clinical course of melanoma. Southeastern Med J 47:196–200

18.

Holly EA (1986) Melanoma and pregnancy. Recent Results Cancer Res 102:118–126PubMed

19.

Houghton AM, Flannery J, Viola MV (1981) Malignant melanoma of the skin occurring during pregnancy. Cancer 48:407–410PubMedCrossRef

20.

Reintgen DS, McCarty KS Jr, Vollmer R, Cox E, Seigler HF (1985) Malignant melanoma and pregnancy. Cancer 55:1340–1344PubMedCrossRef

21.

McManamny DS, Moss ALH, Pocock PV, Briggs JC (1989) Melanoma and pregnancy: a long-term follow-up. Br J Obstet Gynaecol 96:1419–1423PubMed

22.

Wong JH, Sterns EE, Kopald KH, Nizze JA, Morton DL (1989) Prognostic significance of pregnancy in stage I melanoma. Arch Surg 124:1227–1231PubMed

23.

Slingluff CL Jr, Reintgen DS, Volmer RT, Seigler HF (1990) Malignant melanoma arising during pregnancy—a study of 100 patients. Ann Surg 211:552–559PubMedCrossRef

24.

MacKie RM, Bufalino R, Morabito A, Sutherland C, Cascinelli N (1991) Lack of effect of pregnancy on outcome of melanoma—the World Health Organisation melanoma programme. Lancet 337:653–655PubMedCrossRef

25.

O’Meara AT, Cress R, Xing G, Danielsen B, Smith LH (2005) Malignant melanoma in pregnancy. A population-based evaluation. Cancer 103(6):1217–1226PubMedCrossRef

26.

Martin AG, Leal-Khouri S (1992) Physiologic skin changes associated with pregnancy. Int J Dermatol 31:375–378PubMedCrossRef

27.

Pennoyer JW, Grin CM, Driscoll MS, Dry SM, Walsh SJ, Gelineau JP et al (1997) Changes in size of melanocytic nevi during pregnancy. J Am Acad Dermatol 36(3 Pt 1):378–382PubMedCrossRef

28.

Travers RL, Sober AJ, Berwick M, Mihm MC Jr, Barnhill RL, Duncan LM (1995) Increased thickness of pregnancy-associated melanoma. Br J Dermatol 132(6):876–883PubMedCrossRef

29.

Resnick R (1999) Cancer during pregnancy. N Engl J Med 341:120–121CrossRef

30.

Leslie KK, Espey E (2005) Oral contraceptives and skin cancer: is there a link? Am J Clin Dermatol 6(6):349–355PubMedCrossRef

31.

Feskanich D, Hunter DJ, Willett WC, Spiegelman D, Stampfer MJ, Speizer FE et al (1999) Oral contraceptive use and risk of melanoma in premenopausal women. Br J Cancer 81(5):918–923PubMedCrossRef

32.

Pfahlberg A, Hassan K, Wille L, Lausen B, Gefeller O (1997) Systematic review of case–control studies: oral contraceptives show no effect on melanoma risk. Public Health Rev 25:309–315PubMed

33.

Karagas MR, Stukel TA, Dykes J, Miglionico J, Greene MA, Carey M et al (2002) A pooled analysis of 10 case–control studies of melanoma and oral contraceptive use. Br J Cancer 86(7):1085–1092PubMedCrossRef

34.

Durvasula R, Ahmed SM, Vashisht A, Studd JW (2002) Hormone replacement therapy and malignant melanoma: to prescribe or not to prescribe? Climacteric 5(2):197–200PubMedCrossRef

35.

Grin CM, Driscoll MS, Grant-Kels JM (1998) The relationship of pregnancy, hormones, and melanoma. Semin Cutan Med Surg 17(3):167–171PubMedCrossRef

36.

Baergen RN, Johnson D, Moore T et al (1997) Maternal melanoma metastatic to the placenta: a case report and review of the literature. Arch Pathol Lab Med 121:508–511PubMed

37.

Alexander A, Samlowski WE, Grossman D, Bruggers CS, Harris RM, Zone JJ et al (2003) Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. J Clin Oncol 21(11):2179–2186CrossRef

38.

Anderson JF, Kent S, Machin GA (1989) Maternal malignant melanoma with placental metastasis: a case report with literature review. Pediatr Pathol 9:35–42PubMedCrossRef

Title: Melanoma in relation to reproductive and hormonal factors in women: current review on controversial issues
Authors: Marko Lens
Veronique Bataille
Publication date: 01-06-2008
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 5/2008
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-008-9110-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2008

A new method to evaluate the completeness of case ascertainment by a cancer registry

Vegetables- and antioxidant-related nutrients, genetic susceptibility, and non-Hodgkin lymphoma risk

Temporal trends in breast cancer mortality by state and race

A cancer incidence survey in Tianjin: the third largest city in China—between 1981 and 2000

Cancer mortality and farming in South Korea: an ecologic study

Disinfection byproducts in drinking water and skin cancer? A hypothesis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer